ライフサイエンスコーパス: median time

1 The median time between invitations (2.37 years) was used as a cu

2 The median time delay between research PET and surgery was 2 d.

3 The median time from approval to first postmarket safety event wa

4 djusted risk of death for each type of synucleinopathy, the median time from diagnosis to death, and the causes of death.

5 iagnosis was used for assessment of post-diagnostic intake (median time from diagnosis to the dietary assessment, 2.2 yea

6 The median incubation period was 1 day, and the median time from illness onset to hospital admission was 2 da

7 ed patients (mean age, 44 years [SD, 15]; women, 274 [57%]; median time from orthopedic implant placement, 11 months [int

8 The median time from palliative care consultation to death was 10

9 (mean age = 66 years, median NIH Stroke Scale [NIHSS] = 16, median time from symptom onset to endovascular therapy = 5.2

10 The median time from week 24 to the first intravitreal aflibercep

11 n the time from PSC door in to door out that reduced from a median time of 104 minutes (95% CI, 82-112 minutes) to a medi

12 ion was immediate in 61.5% of patients and occurred after a median time of 3 hours after extracorporeal life support impl

13 ssociated MN, eight of whom developed a malignancy within a median time of 3 months from diagnosis of MN.

14 Cryptosporidiosis occurred at a median time of 3.4 (0-19.8) years posttransplant.

15 a median time of 104 minutes (95% CI, 82-112 minutes) to a median time of 64 minutes (95% CI, 51-71.0 minutes) (P < .001

16 The median size was 3.6 cm (1.6-5.5 cm), and occurred at a median time of 65.5 months (2-183 months) posttransplant.

17 The median time of day for extubation with an extubation readines

18 Median time of death for patients with FMF was 61 months (ran

19 Serum samples were collected over a median time period of 10 years and analyzed for antibodies to

20 ed between 1310 ng/mL and 34 800 ng/mL and was reached in a median time (tmax) between 1.5 h and 4 h, with a mean elimina

21 The median time to antimicrobial was 3.77 hours (interquartile ra

22 Compared with a median time to clinical response of 5.14 days in the 600 mg i

23 of 5.14 days in the 600 mg intravenous zanamivir group, the median time to clinical response was 5.87 days (difference of

24 In both groups, median time to collection of treatment was within 1 day of re

25 The median time to death was 4.2 years (IQR, 2.2-7.1 years).

26 Among eyes without DDAF at first visit, the median time to develop a DDAF lesion was 4.9 years (95% CI, 4

27 Teledermatology reduced median time to evaluation from 70.0 days (interquartile range

28 Median time to first follow-up RHC was 4.6 months (interquart

29 Median time to fixation was 15 hours (IQR 7-24 hours) and del

30 rom initial treatment was 100 months (14-365 months), while median time to local recurrence was 43 months (9-185 months).

31 prior to 9 or 9.25 Gy total body irradiation (TBI) reduced median time to moribund in mice to 8 days.

32 Median time to onset of select AEs ranged from 5 weeks for sk

33 The median time to platelet engraftment was 27 days.

34 Median time to progression and duration of response were 9.5

35 The median time to progression and median progression-free surviv

36 The median time to progression was 57.3 months (95% CI 44.2-73.3)

37 Median time to PTLD diagnosis was 8.3 (range, 1.2-13.9) years

38 Median time to recurrence was 14 months, and median follow-up

39 Median time to response was approximately 1.8 months.

40 After band removal, the median time to revisional surgery was 1 year (95% confidence

41 Median time to second-line DST was 53 days (range, 8-259).

42 The median time to the first crisis was significantly longer with

43 an with placebo (4.07 vs. 1.38 months, P=0.001), as was the median time to the second crisis (10.32 vs. 5.09 months, P=0.

44 Median time to transplantation for such patients is double th

45 R], 33.25-83.0 days) to 0.5 days (IQR, 0.172-0.94 days) and median time to treatment from 73.5 to 3.0 days compared with

46 l treatment that blocks viral replication, showing that the median time to undetectable plasma viral load (VL) can be red

47 Excluding those with resistant virus, the median time to virus negativity was 5.5 days in pocapavir rec

48 E events occurred after hospital discharge, with a 19.5-day median time to VTE.

49 Median times to death of patients at high (0.94 years, n = 31

50 E/S achieved a significantly lower median time-weighted average low-density lipoprotein choleste